StreetAlpha.app
Home › Stocks › ZYME

Zymeworks Inc. (ZYME)

$25.84
▼ −2.31%
LAST CLOSE · NOV 17

Zymeworks develops antibody medicines for cancer and immune diseases and partners with drugmakers to sell them. It last closed at $25.84 on Nov 17, down 2.31% on the day. ZYME last reported earnings on Mon, Nov 9, 2026. The average 12-month price target from 6 analysts is $41.17 (+59.3% from the last close), with a high of $56.00 and a low of $33.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell).

AI Auto Pilots
Is ZYME in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$266.0M
+97.8% vs a year ago
Net income
$43.3M
16.3% margin
EPS (diluted)
$0.53
Free cash flow
−$112.8M
−42.4% margin
Valuation
Market cap
$1.8B
69.0M shares
P/E
48.8
Price over 12 month EPS
Price to sales
6.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$100.5M
At Sep 30
Debt
$338.9M
At Sep 30
Shareholder equity
$258.3M
Buybacks
$165.6M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $26.7M$26.7MFY2021FY2022: $412.5M$412.5MFY2022FY2023: $76.0M$76.0MFY2023FY2024: $76.3M$76.3MFY2024FY2025: $106.0M$106.0MFY2025

From ZYME's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · After the close (AMC)
Reported EPS
$2.28
vs $2.40 est. · miss
Year-ago EPS
-$0.26
Same quarter last year
Options-implied move
±8.2%
Priced in before that report
Analyst consensus
Strong Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
6firms
6 Buy0 Hold0 Sell
Each firm's latest rating on ZYME in the past 90 days
Average 12-month target
$41.17
▲ 59.3% upside

Based on 6 analysts who set a price target on ZYME in the past 90 days. The average target is $41.17, with a high of $56.00 and a low of $33.00, compared with the last close of $25.84.

Low $33.00Avg $41.17High $56.00
Blue marker: last close $25.84
Highest target$56.00
Average target$41.17
Lowest target$33.00
Latest rating changes
CitizensMaintained
Nov 13Buy$39
CitigroupTarget raised
Nov 11Buy$39 → $44
TD CowenMaintained
Nov 10Buy$39
Truist SecuritiesTarget raised
Nov 10Buy$35 → $36
HC Wainwright & Co.Target raised
Nov 10Buy$55 → $56
DateFirmActionRatingPrice target
Nov 13CitizensMaintainedBuy$39
Nov 11CitigroupTarget raisedBuy$39 → $44
Nov 10TD CowenMaintainedBuy$39
Nov 10Truist SecuritiesTarget raisedBuy$35 → $36
Nov 10HC Wainwright & Co.Target raisedBuy$55 → $56
Loading…

Technical Analysis

ZYME · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold

The stock is 11% below its 20 day and 5% below its 50 day average. It is 1% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 41), near oversold. The nearest support is the swing low (Sep 15) at $25.81, and the nearest resistance the Pivot at $25.96.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 5.4%/day
Key levels
$31.9452 week high+23.6%
$28.6520 day average+10.9%
$27.2250 day average+5.3%
$26.40100 day average+2.2%
$26.40Pivot R1+2.2%
$26.19Swing high (May 27)+1.4%
$25.96Pivot+0.5%
$25.84Last close
$25.81Swing low (Sep 15)−0.1%
$25.56200 day average−1.1%
$25.41Pivot S1−1.7%
$21.5252 week low−16.7%
Indicators
RSI (14)40.77Middle of its rangeNeutral
MACD-0.03Below its signal lineBearish
Stochastic7.4Near the bottom of its rangeOversold
ADX (14)21.9Weak trend
Williams %R-95.2Oversold below −80, overbought above −20Oversold
CCI (20)-166.5Oversold below −100, overbought above 100Oversold
Rate of change−14.2%Change over 10 sessionsBearish
ATR (14)$1.39Typical daily range, 5.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for ZYME

What happened before

See how ZYME did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ZYME usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ZYME has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ZYME in the last 90 days.

Loading…

See today’s whale options flow across the market →

ZYME Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲107 buying vs 83 selling
  • ▼Held by funds -1.4 pts
  • ●Funds holding -1
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding203204−0.5%
In funds' top 1043+33.3%
Held by funds99.5%100.9%−1.4 pts
New / increased28 / 7923 / 62+25.9%
Reduced / sold out55 / 2873 / 30−19.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ZYME institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZYME is in one of them and how their past ZYME trades turned out.

ZYME in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ZYME in an article yet. Here's the latest on the wider market.

About Zymeworks

Zymeworks is a biotechnology company based in Middletown, Delaware. It develops medicines built from antibodies for cancer, inflammation and autoimmune disease, using its own technology platforms. Its partners are drugmakers that share development costs and sell the treatments, and Zymeworks earns milestone payments and royalties from those partnerships.

Headquarters
Middletown, DE
Founded
2003